Navigation Links
UM Ventures Announces Collaboration Between UM School Of Medicine's Dr. Frank Robb and Fina Biosolutions
Date:7/11/2013

BALTIMORE, July 11, 2013 /PRNewswire/ --  University of Maryland (UM) Ventures announced today a collaboration between Frank Robb, Ph.D., at the Institute of Marine and Environmental Technology, and Department of Microbiology & Immunology at the University of Maryland School of Medicine, and Rockville, Maryland-based Fina Biosolutions LLC to devise new ways to manufacture a key component used in many vaccines. The international nonprofit organization, PATH, which spurs new innovation with the goal of delivering high-impact, low-cost global health solutions such as lifesaving vaccines, will fund the partnership's development efforts as part of its pneumococcal vaccine project.

"A new and improved vaccine production method is the goal of this public-private partnership between my lab and Fina Biosolutions," said Dr. Robb. "It is designed to yield broader availability of an important vaccine component, which is highly effective, but prohibitively expensive for some applications, particularly in the developing world."

Dr. Robb, whose lab is in the Institute of Marine and Environmental Technology, has studied a unique group of microbes found in extreme environments ("extremophiles"). These astonishing organisms, many of them from marine hydrothermal vents (so-called "Black Smokers"), have chaperone systems that enable them to survive and even thrive in extreme heat and harsh chemical conditions. When the extremophile chaperone systems are transferred to ordinary bacteria, they become more stable to heat or solvent exposure. Dr. Robb's team has developed several technologies, patented by the University of Maryland, which are based on industrial applications of his research. These include systems for improving the stability and function of manufactured proteins for a variety of purposes, such as vaccines and specialty enzymes.

"We are pleased to be working with organizations that share FinaBio's mission to help make conjugate vaccines affordable for the emerging markets. The partnership with PATH and the University of Maryland will allow us to achieve this goal and to help to make vaccines that will save countless lives," said Andrew Lees, Ph.D., Scientific Director, Fina Biosolutions.

"Following on the heels of our Wellcome Trust-Bharat Biotech collaboration formed last year," said Phil Robilotto, Assistant Vice President, Office of Technology Transfer, UMB, "UMB's Office of Technology Transfer, in conjunction with UM Ventures, is very happy to be facilitating more of these important public-private partnerships on behalf of the campus and its investigators, such as Dr. Robb." UM Ventures is designed to help facilitate the commercialization of technologies developed by UM researchers at the University's Baltimore and College Park campuses.

About Fina Biosolutions, LLC

Fina Biosolutions LLC is a private, research and development-stage biotechnology company that discovers, develops, and collaborates to commercialize novel vaccine conjugates for prevention of life-threatening diseases. Fina has patented novel techniques to conjugate, purify, and manufacture conjugates using its proprietary chemistry to create complex conjugate vaccines. For more information, see http://www.finaBiosolutions.com/.

About PATH

PATH is an international nonprofit organization that transforms global health through innovation. We take an entrepreneurial approach to developing and delivering high-impact, low-cost solutions from lifesaving vaccines, drugs, diagnostics, and devices to collaborative programs with communities. Through our work in more than 70 countries, PATH and our partners empower people to achieve their full potential. For more information, please visit http://www.path.org/.

About UM Ventures

UM Ventures is an ambitious joint research commercialization effort of the University of Maryland, Baltimore (UMB) and the University of Maryland, College Park (UMCP). UM Ventures is a central part of an initiative called University of Maryland: MPowering the State. The program has combined the entrepreneurial efforts of the two powerhouse universities that together do more than $1 billion a year in externally sponsored research. UM Ventures is bringing innovative technologies to the market and expanding collaborations with industry. Visit http://umventures.org/ to learn more.


'/>"/>
SOURCE UM Ventures
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunpeaks Ventures Files Defamation Lawsuit
2. Practice Fusion Announces $34 Million in Financing Led by Artis Ventures
3. Pappas Ventures Names Pat Gage to Scientific Advisory Board
4. SJF Ventures Completes Oversubscribed Series A Round for BioSurplus
5. Sunpeaks Ventures Announces Second Quarter 2012 Results
6. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
7. Thesan Pharmaceuticals gibt Serie-A-Finanzierung unter gemeinsamer Führung von Novo Ventures und Novartis Venture Funds bekannt
8. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
9. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
10. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
11. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., a ... , today announced that the company has provided an ... of North Carolina at Chapel Hill and to Qura ... to characterize and quantify HIV reservoir and viral expression ... intervention. The HIV Cure Center is a joint initiative ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 ... bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner for people ... such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in ...
(Date:8/18/2017)... ... August 18, 2017 , ... 800response, the ... monitoring solutions, announced today the launch of a redesigned corporate website, 800response.com ... aesthetic, fully responsive design, and an enhanced search directory for businesses and advertising ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... “Beyond Our ... fulfilled life. “Beyond Our Imaginations: The Infinite God” is the creation of published author, ... across the country. , Lawrence shares, “The problem with becoming a greater man of ...
(Date:8/18/2017)... ... 18, 2017 , ... “Prompted By Love”: a love story thrown into doubt ... Nettles. Author Mary P. Nettles has devoted her life to ministry since the ... lifelong desire to write was, however, not fulfilled until 2014 when "The Color of ...
(Date:8/17/2017)... ... August 17, 2017 , ... Shared leadership between physicians ... effective, very effective, or effective by 85% of respondents, according to the recent ... Reports are based on surveys of the NEJM Catalyst Insights Council, a qualified ...
Breaking Medicine News(10 mins):